全部| 求助中| 待确认 按时间排序|按积分排序

卓國雄、盧俊宏（2005）。中文版表現失敗評估量表之修訂研究：探索性和驗證性因素分析。大專體育學刊，7(2)，111-123。

用户TxIAy2KCY7IE 22天前 10 已完结

Extending the Treatment Window for Intravenous Thrombolysis in Acute Ischemic Stroke

答案Answerball 22天前 10 已完结

Multiomics Integration Identifies a Molecular Subtype of Intrahepatic Cholangiocarcinoma With Enhanced Benefit From Adjuvant Therapy

用户odusrbT5lLew 22天前 10 已完结

Multiomics Integration Identifies a Molecular Subtype of Intrahepatic Cholangiocarcinoma With Enhanced Benefit From Adjuvant Therapy

用户odusrbT5lLew 22天前 10 已关闭

Integrative multi-omics identifies cholangiolocarcinoma as a distinct molecular subtype of intrahepatic cholangiocarcinoma

用户odusrbT5lLew 22天前 10 已关闭

Futibatinib after non-covalent FGFR inhibitors in FGFR2-rearranged intrahepatic cholangiocarcinoma: clinical activity and resistance patterns

用户odusrbT5lLew 22天前 10 已完结

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

用户odusrbT5lLew 22天前 10 已完结

Tegileridine vs . sufentanil for postoperative analgesia in general surgery: A prospective, randomized, controlled, non‐inferiority trial.

用户Jw4mQk-WLx9o 22天前 10 已完结

Convergence of Local and Systemic Therapies: A Comprehensive Society of Interventional Oncology Framework for 90 Y Radioembolization with Immunotherapy in HCC

用户odusrbT5lLew 22天前 10 已完结

Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti‐PD‐1 immunotherapy for unresectable intrahepatic cholangiocarcinoma

用户odusrbT5lLew 22天前 10 已完结
首页 上页 59 60 61 62 63 64 65 下页

wispass工作室 Copyright © 蜀ICP备20005939号-4 www.wispass.com